Challenges in the laboratory analyses of bleeding disorders

Thrombosis Research

Volumn 130, Issue 1, 2012, Pages 1-6

  Chitlur, Meera ^a,b  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b NONE   (United States)

Author keywords

Bypassing agents; Coagulation assay; Global hemostasis assay; Hemophilia; Inhibitors; Laboratory challenges

Indexed keywords

BLOOD CLOTTING FACTOR 8; FIBRIN; THROMBIN;

BLEEDING DISORDER; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD CLOTTING TEST; FIBRINOLYSIS; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; KINETICS; LABORATORY DIAGNOSIS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; THROMBIN TIME; THROMBOCYTE POOR PLASMA; THROMBOCYTE RICH PLASMA; THROMBOELASTOGRAPHY; THROMBOELASTOMETRY; THROMBOPHILIA;

EID: 84861799209     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.03.011     Document Type: Review

References (64)

1. NovoSeven® RT [Coagulation Factor VIIa (Recombinant) Room Temperature] [package insert] August 2010 Novo Nordisk A/S Bagsvaerd, Denmark
2. FEIBA NF (Anti-Inhibitor Coagulant Complex) Nanofiltered and Vapor Heated [package insert] February 2011 Baxter Healthcare Corporation Westlake Village, CA
3. A.H. Kamal, A. Tefferi, and R.K. Pruthi How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults Mayo Clin Proc 82 2007 864 873
4. B. Verbruggen, P. Meijer, I. Novakova, and W. Van Heerde Diagnosis of factor VIII deficiency Haemophilia 14 Suppl. 3 2008 76 82
5. G. Lippi, M. Franchini, and E.J. Favaloro One-stage clotting versus chromogenic assays for assessing recombinant factor VIII: two faces of a haemostasis coin Blood Coagul Fibrinolysis 20 2009 1 3
6. A. Parquet-Gernez, C. Mazurier, and M. Goudemand Functional and immunological assays of FVIII in 133 haemophiliacs-characterization of a subgroup of patients with mild haemophilia A and discrepancy in 1- and 2-stage assays Thromb Haemost 59 1988 202 206
7. Z. Rudzki, E.M. Duncan, G.J. Casey, M. Neumann, E.J. Favaloro, and J.V. Lloyd Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods Br J Haematol 94 1996 400 406
8. H. Lyall, M. Hill, J. Westby, C. Grimley, and G. Dolan Tyr346->Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype - is this mild haemophilia A? Haemophilia 14 2008 78 80
9. A.L. Poulsen, L.H. Pedersen, A.M. Hvas, L.H. Poulsen, H. Thykjaer, and J. Ingerslev Assay discrepancy in mild haemophilia A: entire population study in a National Haemophilia Centre Haemophilia 15 2009 285 289
10. A.R. Cid, M. Calabuig, V. Cortina, P. Casana, S. Haya, and A. Moret One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype Haemophilia 14 2008 1049 1054
11. A. McCraw, A. Hillarp, and M. Echenagucia Considerations in the laboratory assessment of haemostasis Haemophilia 16 Suppl. 5 2010 74 78
12. D. Adcock, D. Kressin, and R.A. Marlar The effect of time and temperature variables on routine coagulation tests Blood Coagul Fibrinolysis 9 1998 463 470
13. M. Shima, T. Matsumoto, and K. Ogiwara New assays for monitoring haemophilia treatment Haemophilia 14 Suppl. 3 2008 83 92
14. R.A. Marlar, P.J. Bauer, J.L. Endres-Brooks, R.R. Montgomery, C.M. Miller, and M.M. Schanen Comparison of the sensitivity of commercial APTT reagents in the detection of mild coagulopathies Am J Clin Pathol 82 1984 436 439
15. A. Bowyer, S. Kitchen, and M. Makris The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies Int J Lab Hematol 33 2011 154 158
16. Christine A. Lee, EEB, and W. Keith Hoots Global laboratory assays in hemophilia Christine A. Lee, EEB W. Keith Hoots, Textbook of hemophilia 2nd ed. 2010 Blackwell Publishing Ltd West Sussex 263 268
17. S.C. Nair, Y. Dargaud, M. Chitlur, and A. Srivastava Tests of global haemostasis and their applications in bleeding disorders Haemophilia 16 Suppl. 5 2010 85 92
18. T.W. Barrowcliffe Monitoring inhibitor patients with the right assays Semin Hematol 45 2008 S25 S30
19. J.J. van Veen, A. Gatt, A.E. Bowyer, P.C. Cooper, S. Kitchen, and M. Makris Calibrated automated thrombin generation and modified thromboelastometry in haemophilia A Thromb Res 123 2009 895 901
20. H.C. Hemker, and S. Beguin Thrombin generation in plasma: its assessment via the endogenous thrombin potential Thromb Haemost 74 1995 134 138
21. R. Luddington, and T. Baglin Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition J Thromb Haemost 2 2004 1954 1959
22. J.J. van Veen, A. Gatt, P.C. Cooper, S. Kitchen, A.E. Bowyer, and M. Makris Corn trypsin inhibitor in fluorogenic thrombin-generation measurements is only necessary at low tissue factor concentrations and influences the relationship between factor VIII coagulant activity and thrombogram parameters Blood Coagul Fibrinolysis 19 2008 183 189
23. Y. Dargaud, and C. Negrier Thrombin generation testing in haemophilia comprehensive care centres Haemophilia 16 2010 223 230
24. B. Sorensen, and J. Ingerslev Thromboelastography and recombinant factor VIIa-hemophilia and beyond Semin Hematol 41 2004 140 144
25. A. Kupesiz, M. Rajpurkar, I. Warrier, W. Hollon, O. Tosun, and J. Lusher Tissue plasminogen activator induced fibrinolysis: standardization of method using thromboelastography Blood Coagul Fibrinolysis 21 2010 320 324
26. T.W. Barrowcliffe, M. Cattaneo, G.M. Podda, P. Bucciarelli, F. Lussana, and A. Lecchi New approaches for measuring coagulation Haemophilia 12 Suppl. 3 2006 76 81
27. N.A. Goldenberg, W.E. Hathaway, L. Jacobson, and M.J. Manco-Johnson A new global assay of coagulation and fibrinolysis Thromb Res 116 2005 345 356
28. N.A. Goldenberg, W.E. Hathaway, L. Jacobson, K. McFarland, and M.J. Manco-Johnson Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A Haemophilia 12 2006 605 614
29. N.A. Goldenberg, C. Bombardier, W.E. Hathaway, K. McFarland, L. Jacobson, and M.J. Manco-Johnson Influence of factor IX on overall plasma coagulability and fibrinolytic potential as measured by global assay: monitoring in haemophilia B Haemophilia 14 2008 68 77
30. M.A. Escobar Recombinant Factor VIIa: The Possibilities for Monitoring Transfus Altern Tranfus Med 5 2003 51 54
31. R. Gilmore, S. Harmon, C. Gannon, M. Byrne, J.S. O'Donnell, and P.V. Jenkins Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy Haemophilia 16 2010 671 674
32. Y. Dargaud, S. Beguin, A. Lienhart, R. Al Dieri, C. Trzeciak, and J.C. Bordet Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B Thromb Haemost 93 2005 475 480
33. S. Eichinger, B. Lubsczyk, M. Kollars, L. Traby, K. Zwiauer, and A. Gleiss Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa Eur J Clin Invest 39 2009 707 713
34. B. Sorensen, and J. Ingerslev Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa J Thromb Haemost 2 2004 102 110
35. M. Chitlur, I. Warrier, M. Rajpurkar, W. Hollon, L. Llanto, and C. Wiseman Thromboelastography in children with coagulation factor deficiencies Br J Haematol 142 2008 250 256
36. D. Viuff, S. Andersen, B.B. Sorensen, and S. Lethagen Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven) therapy in haemophilia A patients Thromb Res 126 2010 144 149
37. L. Spiezia, L. Meneghetti, F. Dalla Valle, G. Tognin, C. Radu, and G. Saggiorato Potential role of thrombelastography in the monitoring of acquired factor VIII inhibitor hemophilia A: report on a 78-year-old woman with life-threatening bleedings Clin Appl Thromb Hemost 15 2009 470 476
38. G. Kenet, C.B. Stenmo, A. Blemings, W. Wegert, J. Goudemand, and M. Krause Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial Thromb Haemost 103 2010 351 359
39. K. Ghosh, S. Shetty, and B. Kulkarni Correlation of thromboelastographic patterns with clinical presentation and rationale for use of antifibrinolytics in severe haemophilia patients Haemophilia 13 2007 734 739
40. M. Shima, T. Matsumoto, K. Fukuda, Y. Kubota, I. Tanaka, and K. Nishiya The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C) Thromb Haemost 87 2002 436 441
41. S. Kasuda, I. Tanaka, M. Shima, T. Matsumoto, Y. Sakurai, and K. Nishiya Effectiveness of factor VIII infusions in haemophilia A patients with high responding inhibitors Haemophilia 10 2004 341 346
42. T. Inoue, M. Shima, M. Takeyama, T. Matsumoto, K. Nishiya, and I. Tanaka Higher recovery of factor VIII (FVIII) with intermediate FVIII/von Willebrand factor concentrate than with recombinant FVIII in a haemophilia A patient with an inhibitor Haemophilia 12 2006 110 113
43. C.J. Rea, J.H. Foley, J. Ingerslev, and B. Sorensen Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A J Thromb Haemost 9 2011 510 516
44. M. Franchini, and G. Lippi Acquired factor VIII inhibitors Blood 112 2008 250 255
45. E. Persson, G. Bolt, T.D. Steenstrup, and M. Ezban Recombinant coagulation factor VIIa-from molecular to clinical aspects of a versatile haemostatic agent Thromb Res 125 2010 483 489
46. D. Bolliger, F. Szlam, R.J. Molinaro, M.A. Escobar, J.H. Levy, and K.A. Tanaka Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa Haemophilia 16 2010 510 517
47. J. Klintman, E. Berntorp, and J. Astermark Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A Haemophilia 16 2010 e210 e215
48. Y. Dargaud, A. Lienhart, S. Meunier, O. Hequet, H. Chavanne, and V. Chamouard Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision Haemophilia 11 2005 552 558
49. Y. Dargaud, A. Lienhart, and C. Negrier Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery Blood 116 2010 5734 5737
50. Y. Dargaud, J.C. Bordet, A. Lienhart, and C. Negrier Use of the thrombin generation test to evaluate response to treatment with recombinant activated factor VII Semin Hematol 45 2008 S72 S73
51. T. Livnat, U. Martinowitz, A. Zivelin, and U. Seligsohn Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma Haemophilia 14 2008 782 786
52. G. Young, R. Blain, P. Nakagawa, and D.J. Nugent Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography Haemophilia 12 2006 598 604
53. G. Young, L.S. Ebbesen, D. Viuff, J. Di Paola, B.A. Konkle, and C. Negrier Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial Blood Coagul Fibrinolysis 19 2008 276 282
54. G. Young, R. Zhang, R. Miller, D. Yassin, and D.J. Nugent Comparison of kaolin and tissue factor activated thromboelastography in haemophilia Haemophilia 16 2010 518 524
55. M. Lak, B. Scharling, A. Blemings, R. Sharifian, Z. Maleki, and A. Daraee Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram Haemophilia 14 2008 103 110
56. F. Ismael, J. van der Meer, J.T. de Wolf, K. Kuizenga, L.P. Aarts, and H.G. Hendriks Thromboelastographic evaluation of recombinant factor VIIa in a child with Glanzmann's thrombasthenia Anesth Analg 103 2006 791 792
57. M. Shima Understanding the hemostatic effects of recombinant factor VIIa by clot wave form analysis Semin Hematol 41 2004 125 131
58. F.E. Preston, G. Lippi, E.J. Favaloro, G.R. Jayandharan, E.S. Edison, and A. Srivastava Quality issues in laboratory haemostasis Haemophilia 16 Suppl. 5 2010 93 99
59. D.P. Kitchen, S. Kitchen, I. Jennings, T. Woods, and I. Walker Quality assurance and quality control of thrombelastography and rotational Thromboelastometry: the UK NEQAS for blood coagulation experience Semin Thromb Hemost 36 2010 757 763
60. I. Jennings, D.P. Kitchen, T.A. Woods, S. Kitchen, and I.D. Walker Emerging technologies and quality assurance: the United Kingdom National External Quality Assessment Scheme perspective Semin Thromb Hemost 33 2007 243 249
61. C. Kluft, and P. Meijer External quality assessment for thrombin generation tests: an exploration Semin Thromb Hemost 36 2010 791 796
62. Y. Dargaud, R. Luddington, E. Gray, T. Lecompte, T. Siegemund, and T. Baglin Standardisation of thrombin generation test-which reference plasma for TGT? An international multicentre study Thromb Res 125 2010 353 356
63. M. Chitlur, and J. Lusher Standardization of thromboelastography: values and challenges Semin Thromb Hemost 36 2010 707 711
64. M. Chitlur, B. Sorensen, G.E. Rivard, G. Young, J. Ingerslev, and M. Othman Standardization of thromboelastography: a report from the TEG-ROTEM working group Haemophilia 17 2011 532 537